Weigh! The chemical medicine market has stepped into a trillion era, and the top 10 drugs for chronic diseases have dominated the screen, and the sales of several key monitoring products have declined

In the era of trillions of chemical medicine market, public hospitals are still the big end of sales In 2018, the sales volume of terminal chemical drugs of public medical institutions (urban public hospitals, county-level public hospitals, urban community centers and township hospitals) in China was 1032.5 billion yuan, up 7.36% year on year China's public medical institutions terminal chemical sales have entered a trillion era! Sales of terminal chemicals in public medical institutions in China (unit: 100 million yuan) from the perspective of channel pattern, urban public hospitals are still the largest sales terminal, but in recent years, due to the deepening of public hospital reform, the promotion of hierarchical diagnosis and treatment, medical insurance control fees and other policies, the growth rate of sales slowed down In 2018, China's public medical institutions' end-to-end chemical drug channel pattern 6 pharmaceutical market exceeded 100 billion, 3 pharmaceutical market exceeded 10% growth rate In terms of the market share of chemical drugs, the market share of six drugs, including systemic anti infective drugs, digestive system and metabolic drugs, blood and hematopoietic system drugs, anti-tumor and immunomodulators, cardiovascular system drugs, nervous system drugs, accounts for more than 10%, and the sales volume exceeds 100 billion yuan From the perspective of sales growth rate, the growth rate of drugs in more than 100 billion yuan in many markets slowed down However, the sales growth of anti-tumor and immunomodulators, musculoskeletal system, systemic hormone preparations (excluding sex hormones) and other drugs has exceeded 10% In 2018, the large-scale sales of terminal drugs in China's public medical institutions: AstraZeneca, a multinational pharmaceutical company, continues to dominate the screen From the perspective of the sales pattern of the manufacturers, AstraZeneca is the leader of foreign companies in the domestic market, while Sanofi continues to rank the third; the domestic enterprises Hengrui, Yangzijiang and Qilu continue to hold the top 10 list The sales growth of top 10 manufacturers is still very strong, and Roche leads with a sales growth rate of more than 20% With the pharmaceutical industry stepping into the deep water range of medical reform, the industry concentration has been further improved, "the stronger the stronger" situation is more obvious In 2018, the sales pattern of terminal manufacturers in public medical institutions in China, top 10 drugs for chronic diseases, and the sales volume of top 10 drugs for key monitoring declined Rosuvastatin calcium tablet is a new member of the top 10 products in 2018 It can be seen that clopidogrel bisulfate tablet, atorvastatin calcium tablet, budesonide suspension for inhalation, acarbose tablet and rosuvastatin calcium tablet are all top 10 chronic disease drugs, and the sales growth is also very strong The sales of clopidogrel bisulfate tablets and atorvastatin calcium tablets exceeded 11 billion yuan With the aging of the population, the market demand for drugs for chronic diseases continues to expand In 2019, the adjustment of the medical insurance catalogue will also give priority to drugs for chronic diseases Under the influence of the auxiliary drug policy, we can see that the sales of some products that are frequently monitored in key categories have generally declined For example, the sales volume of alprostadil for heart disease treatment decreased by 22.92%, falling out of the top ten, and the sales volume of omeprazole sodium for injection and pantoprazole sodium for injection for digestive system decreased by 3.48% and 7.66%, respectively In 2018, the top 10 terminal products of public medical institutions in China from the perspective of brand top 10, the products of multinational and foreign enterprises occupied multiple seats, and the domestic enterprises Yangzi River, Zhengda Tianqing and Hainan Hailing chemical pharmaceutical won three seats The first trimester is still the original research drug Lipitor (atorvastatin calcium tablets), pramiquelinshu (budesonide suspension for inhalation), Plavix (clopidogrel bisulfate tablets) In 2018, China's public medical institutions terminal brand TOP10 conclusion: in 2019, the national level continues to strengthen the supervision of the pharmaceutical industry, the auxiliary drug catalog is to be released in the near future, the second batch of volume catalog is expected to start before the end of September, 30 cities pilot pay by disease diagnosis related group (DRG) With the pharmaceutical industry stepping into the deep water range of medical reform and the pharmaceutical enterprises entering the period of shuffling and transformation, the industry concentration has been further improved Industry trends are also reflected in terminal data Understanding the data development trend is expected to seize market opportunities Welcome to click below to read the original text and experience the data of minenet Source: meter net database data description: the above sales are calculated at the average retail price